DexCom, Inc. (NASDAQ:DXCM) SVP Matthew Vincent Dolan Sells 6,229 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM – Get Rating) SVP Matthew Vincent Dolan sold 6,229 shares of the firm’s stock in a transaction that occurred on Monday, March 13th. The shares were sold at an average price of $106.27, for a total transaction of $661,955.83. Following the completion of the transaction, the senior vice president now owns 35,872 shares of the company’s stock, valued at approximately $3,812,117.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Matthew Vincent Dolan also recently made the following trade(s):

• On Monday, March 6th, Matthew Vincent Dolan sold 226 shares of DexCom stock. The shares were sold at an average price of $114.40, for a total transaction of $25,854.40.

DexCom Stock Performance

NASDAQ:DXCM opened at $113.16 on Wednesday. The company has a market capitalization of $43.73 billion, a PE ratio of 139.27, a P/E/G ratio of 2.62 and a beta of 1.10. DexCom, Inc. has a fifty-two week low of $66.89 and a fifty-two week high of $134.76. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.83 and a current ratio of 1.99. The company has a 50 day simple moving average of $111.05 and a two-hundred day simple moving average of $106.01.

DexCom (NASDAQ:DXCM – Get Rating) last announced its quarterly earnings data on Thursday, February 9th. The medical device company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.26 by $0.08. The company had revenue of $815.20 million during the quarter, compared to the consensus estimate of $814.52 million. DexCom had a net margin of 11.73% and a return on equity of 16.66%. The company’s quarterly revenue was up 16.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.17 EPS. Research analysts anticipate that DexCom, Inc. will post 1.06 earnings per share for the current year.

Institutional Trading of DexCom

Several large investors have recently modified their holdings of DXCM. Sound Income Strategies LLC grew its position in DexCom by 300.0% in the 3rd quarter. Sound Income Strategies LLC now owns 320 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 240 shares during the period. Bivin & Associates Inc. grew its position in DexCom by 300.0% in the 2nd quarter. Bivin & Associates Inc. now owns 360 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 270 shares during the period. Ronald Blue Trust Inc. grew its position in DexCom by 860.5% in the 3rd quarter. Ronald Blue Trust Inc. now owns 365 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 327 shares during the period. James Investment Research Inc. acquired a new stake in DexCom in the 4th quarter valued at $27,000. Finally, Private Trust Co. NA acquired a new stake in DexCom in the 2nd quarter valued at $29,000. Institutional investors and hedge funds own 94.01% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of research reports. Cowen raised their price objective on shares of DexCom from $114.00 to $125.00 and gave the company an “outperform” rating in a report on Friday, February 10th. Barclays raised their price objective on shares of DexCom from $103.00 to $110.00 and gave the company an “equal weight” rating in a report on Monday, February 13th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Friday, February 10th. Stifel Nicolaus raised their price objective on shares of DexCom from $120.00 to $130.00 in a report on Tuesday, December 20th. Finally, Morgan Stanley increased their target price on shares of DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a research report on Friday, January 6th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $123.00.

DexCom Company Profile

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.